HOME >> MEDICINE >> NEWS
FDA approves EPZICOM

Research Triangle Park, NC August 2, 2004 - EPZICOMTM, a new product combining two HIV medicines into one tablet dosed once a day (QD) with no food or fluid requirements, was cleared for prescription use today by the U.S. Food and Drug Administration (FDA). EPZICOM combines two widely-used nucleoside reverse transcriptase inhibitors (NRTIs), EPIVIR(R) (lamivudine, 3TC) and ZIAGEN(R) (abacavir sulfate, ABC) for use in combination with other antiretroviral drugs. The brand name, EPZICOM, is an acronym for EPIVIR and ZIAGEN in COMbination. EPZICOM Tablets are recommended for use in combination with antiretroviral drugs from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors.

GlaxoSmithKline (GSK), manufacturer of EPZICOM, announced today that it is initiating a voucher program for EPZICOM that will provide a 60 day supply of EPZICOM directly to patients at no cost. These vouchers will be available in limited supply through participating healthcare providers for a limited time. Vouchers can be used to initiate antiretroviral therapy for therapy-nave patients or for therapy-experienced patients who require a change in regimen.

"EPZICOM marks an important advance in GSK's ongoing commitment to provide new options in antiretroviral therapy for HIV patients," said Doug Manion, vice president for HIV Clinical Research for the Infectious Diseases Medicines Development Center (MDC) for GSK. "The voucher program will be particularly beneficial to people who are not covered by private health care plans or in specific states where the drug is not yet available on all formularies."

Dr. Manion added that EPZICOM provides patients and treaters with a flexible and potent dosing option that combines two NRTIs that have been widely used in antiretroviral therapy for years. "Prescribers are familiar with these medications, which have an established resistance and long-term safety p
'"/>

Contact: Annie Noland
anoland@pcipr.com
Public Communications Inc.
2-Aug-2004


Page: 1 2 3 4 5

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves EPZICOM

(Date:5/6/2015)... “ SideChef ” was featured on NewsWatch as part of ... coolest applications on the market for iOS, Android, and Windows. Joe ... review and shared with viewers how this application walks users through ... a good navigator people had to know how to read a ... master navigator. Well what if people could “GPS” their way through ...
(Date:5/6/2015)... Denver, Colorado (PRWEB) May 06, 2015 ... own success? , Next month the Centennial State will ... legal, recreational cannabis sales to adults. And while Colorado’s ... rapid growth during that time, it’s also facing some ... the state are currently facing shortages, especially in the ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Marketing ... #1 ranked international water, sanitation and hygiene nonprofit by ... communities across the world and it brings our agency ... CEO of Marketing Maven. “The ongoing relationship between ... available for people to learn about and support the ...
(Date:5/6/2015)... 06, 2015 Inversion Studios, a ... yoga and Pilates classes, provides personalized individual instruction ... starting with its new Pilates Ring magic circle. ... becoming leaner, stronger, more centered and graceful, Inversion ... fresh venue to healthy fitness through yoga and ...
(Date:5/6/2015)... 06, 2015 Anitha Nallari, MD ... Oncology Consultants, Inc. in Columbus, OH. Dr. Nallari will ... special focus in breast cancer, lung cancer, GI and gallbladder ... well as benign hematology. , Dr. Anitha Nallari ... by the American Board of Internal Medicine. She completed her ...
Breaking Medicine News(10 mins):Health News:An Application to Guide Users through Recipes Was Featured on NewsWatch Television 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3
(Date:5/6/2015)... , May 6, 2015   GenSpera, Inc. (OTCQB: ... has entered the national phase application process in 17 countries ... Japan , China , ... . When awarded, the resulting patent application will extend ... entire platform technology, including its lead drug candidate, mipsagargin, until ...
(Date:5/6/2015)...  TriStar Wellness Solutions(R), Inc. (OTCQB: TWSI) a ... the advanced wound care marketplace, announced today that ... wholly owned independent subsidiary HemCon Medical Technologies, Inc. ... Institutes of Health (NIH) to develop a novel ... be delivered by a catheter to control and ...
(Date:5/6/2015)... Inc. (Nasdaq: NXTM ), a leading manufacturer of ... that exceed the top end of its guidance range. ... 2015 increased 10 percent to $79.5 million, compared with ... 2014. The Company,s revenue guidance range for the first ... was driven by outperformance in the System One segment ...
Breaking Medicine Technology:GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations 2Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 2Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 3Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 4Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11
Cached News: